Kowal-Bielecka, O. et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. doi: 10.1136/ard.

Medically reviewed by Stella Bard, MDCREST syndrome, or limited systemic sclerosis, is a rare autoimmune disease that causes ...

Acute and chronic renal diseases remain common complications of systemic sclerosis. Although treatment for acute scleroderma renal crisis may arrest the rapid progression of renal disease ...

The use of menopausal hormone therapy is associated with an increased risk of developing SLE and SSc among women.

Systemic Scleroderma Treatment Market 2032 The systemic scleroderma treatment market is set to grow from USD 1.34 Bn in 2025 to USD 1.99 Bn ...

The treatment of multiple sclerosis (MS) has improved dramatically ... relapse and have improved recovery by lowering the systemic immune system’s attacks on the central nervous system (CNS).

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S.

The following is a summary of "Automated AI-based image analysis for quantification and prediction of interstitial lung disease in systemic sclerosis patients," published in the January 2025 issue of ...

The following is a summary of “A Phase 2 randomised trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients ...

A study from 2021 notes that Raynaud’s phenomenon is one of the most commonly reported causes of pain in systemic scleroderma. There’s no cure for scleroderma yet, but treatment may slow the ...

Because it is rare (the incidence rate for the systemic form is estimated to be 19 new cases per year per 1 million adults), many nurses and physicians have only read about scleroderma.